Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beer

Showing results (791-800 of 888) with videos related to

Pageof 89
Sort By:
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Journal of Virology|February 3, 2017
Mutations during the Adaptation of H9N2 Avian Influenza Virus to the Respiratory Epithelium of Pigs Enhance Sialic Acid Binding Activity and Virulence in MiceW Yang, D Punyadarsaniya, R L O Lambertz, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 16, 2017
Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and DevelopmentJ J Wilkins, Pls Chan, J Chard, et al.
Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 31, 2024
Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection TestAdam H Buchanan, Anne M Lennon, Omair A Choudhry, et al.
The Journal of Urology|July 24, 2007
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge ConferencePhilip W Kantoff, Tomasz M Beer, Anthony V D'Amico, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Pageof 89

Showing results (791-800 of 888) with videos related to

Sort By:
Pageof 89
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Journal of Virology|February 3, 2017
Mutations during the Adaptation of H9N2 Avian Influenza Virus to the Respiratory Epithelium of Pigs Enhance Sialic Acid Binding Activity and Virulence in MiceW Yang, D Punyadarsaniya, R L O Lambertz, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 16, 2017
Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and DevelopmentJ J Wilkins, Pls Chan, J Chard, et al.
Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 31, 2024
Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection TestAdam H Buchanan, Anne M Lennon, Omair A Choudhry, et al.
The Journal of Urology|July 24, 2007
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge ConferencePhilip W Kantoff, Tomasz M Beer, Anthony V D'Amico, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Pageof 89